The present application incorporates by reference entire disclosure of (1) U.S. application Ser. No. 10/768,571 entitled “Pressure Activated Safety Valve with Anti-adherent Coating” filed on Jan. 29, 2004 naming Karla Weaver and Paul DiCarlo as inventors; (2) U.S. application Ser. No. 10/768,565 entitled “Pressure Activated Safety Valve with High Flow Slit” filed on Jan. 29, 2004 naming Karla Weaver and Paul DiCarlo as inventors; (3) U.S. application Ser. No. 10/768,629 entitled “Stacked Membrane For Pressure Actuated Valve” filed on Jan. 29, 2004 naming Karla Weaver and Paul DiCarlo as inventors; (4) U.S. application Ser. No. 10/768,855 entitled “Pressure Actuated Safety Valve With Spiral Flow Membrane” filed on Jan. 29, 2004 naming Karla Weaver and Paul DiCarlo as inventors; and (5) U.S. application Ser. No. 10/768,479 entitled “Dual Well Port Device” filed on Jan. 29, 2004 naming Katie Daly, Kristian DiMatteo and Eric Houde as inventors.
Many medical procedures require repeated and prolonged access to a patient's vascular system. For example, during dialysis treatment blood may be removed from the body for external filtering and purification, to make up for the inability of the patient's kidneys to carry out that function. In this process, the patient's venous blood is extracted, processed in a dialysis machine and returned to the patient. The dialysis machine purifies the blood by diffusing harmful compounds through membranes, and may add to the blood therapeutic agents, nutrients etc., as required before returning it to the patient's body. Typically the blood is extracted from a source vein (e.g., the vena cava) through a catheter sutured to the skin with a distal needle of the catheter penetrating the source vein.
It is impractical and dangerous to insert and remove the catheter for each dialysis session. Thus, the needle and catheter are generally implanted semi permanently with a distal portion of the assembly remaining within the patient in contact with the vascular system while a proximal portion of the catheter remains external to the patient's body. The proximal end is sealed after each dialysis session has been completed to prevent blood loss and infections. However, even small amounts of blood oozing into the proximal end of the catheter may be dangerous, as thrombi can form therein due to coagulation. These thrombi may then be introduced into the patient's vascular system when blood flows from the dialysis machine through the catheter in a later session.
A common method of sealing the catheter after a dialysis session is to shut the catheter with a simple clamp. This method is often unsatisfactory because the repeated application of the clamp may weaken the walls of the catheter due to the stress placed on the walls at a single point. In addition, the pinched area of the catheter may not be completely sealed allowing air to enter the catheter which may coagulate any blood present within the catheter. Alternatively, valves have been used at the opening of the catheter in an attempt to prevent leaking through the catheter when the dialysis machine is disconnected. However, the unreliability of conventional valves has rendered them unsatisfactory for extended use.
The effect of the presence of valves within the flow of blood may cause some potentially harmful effects. When a fluid passes through a restriction such as the valve, its velocity increases and its pressure decreases. If the decrease in pressure is sufficiently large, the pressure may fall below the vapor pressure of the fluid, causing the formation of gas bubbles. The formation of bubbles, or cavitation, in blood flowing through the vascular system may be dangerous to the patient, because the gas bubbles may become trapped in a blood vessel and may impede flow of blood therethrough. Flow recirculation within the valve also may cause deposits of biological material to form in the passages, which also may leave the valve and become lodged in a blood vessel, impeding passage of blood. The recirculation within the valve may also cause damage to the blood cells which pass through the valve.
In one aspect, the present invention is directed to a valve assembly for vascular access, comprising a body defining a lumen adapted for flowing blood, the body including a luer housing for connection with a first blood conduit and a barb housing for connection with a second blood conduit and a plurality of slitted membranes disposed within the body portion, each of the slitted membranes generating a partial pressure drop for flow therethrough, each of the partial pressure drops being smaller than a total pressure drop for flow through the body portion.
The present invention is further directed to a valve assembly for vascular access, comprising a slitted membrane extending across a passage through the valve assembly to selectively block flow of blood therethrough and a luer housing at a first end of the passage for connection with a first blood conduit, a tapered section of the luer housing having a taper angle of between about 125 degrees and about 173 degrees in combination with a barb housing at a second end of the passage for connection with a second blood conduit.
The present invention may be further understood with reference to the following description and the appended drawings, wherein like elements are referred to with the same reference numerals. The present invention is related to medical devices that are used to access the vascular system of a patient, and in particular to pressure activated safety valves used in kidney dialysis catheters. It will be apparent to those of skill in the art that the present invention may be adapted for use in other medical access devices.
Semi-permanently placed catheters may be useful for a variety of medical procedures which require repeated access to a patient's vascular system in addition to the dialysis treatments mentioned above. For example, kidney dialysis may be repeated on a regular basis for extended periods of time. For safety reasons, as well as to improve the comfort of the patient, access to the patient's vascular system may be better carried out with an implantable, semi-permanent vascular access catheter. Many other conditions that require chronic venous supply of therapeutic agents, nutrients, blood products or other fluids to the patient may also benefit from implantable access catheters, to avoid repeated insertion of a needle into the patient's blood vessels. Thus, although the following description focuses on dialysis, those skilled in the art will understand that the invention may be used in conjunction with any of a wide variety of procedures which require long term implantation of catheters within the body.
Examples of such implantable catheters include those manufactured by Vaxcel™, such as the Chronic Dialysis Catheter and the Implantable Vascular Access System. These devices typically are inserted under the patient's skin, and have a distal end which includes a needle used to enter a blood vessel. The devices also have a proximal end extending outside the body for connection with an outside line. These semi-permanent catheters may be sutured to the patient's skin to maintain them in place while the patient goes about his or her normal occupations. In other cases, the catheter may be less permanent, and may only be implanted in the patient for limited periods of time.
When disconnected from the dialysis machine, the catheter 10 remains within the patient, connected to the patient's vascular system. Thus, it is important to securely seal the hub 18 to prevent fluids from escaping therefrom and contaminants from entering the patient's body. For example, although the proximal end of the catheter 10 may be clamped to close it off, if an effective seal is not obtained, the patient runs a serious risk of infection as well as risks of embolisms due to air entering the blood stream. Another risk is that of venous thrombosis, which is due to coagulation of blood in and near the catheter. In addition, leakage from an improperly sealed catheter may expose attending medical staff to a risk of infection by blood borne pathogens. Thus a mechanism is necessary to ensure that the catheter 10 is sealed when not in use.
Conventional clamps or clips have been used to seal medical tubes such as catheter 10 between medical sessions. However, as the sealing forces repeatedly applied by these clips are exerted on a small portion of the surface area of the catheter 10, damage to the wall of the catheter 10 at this portion can significantly reduce the effective life of the catheter 10. It is also desirable to improve the resistance of a sealing mechanism for the catheter 10 to forces applied during activities of the patient, so that the sealing mechanism will remain effective without restricting the activity of the patient. Finally, it is desirable to minimize the bulk of the sealing mechanism to enhance patient comfort.
An alternative to clamping or clipping the catheter 10 is to include self sealing valves near the entrance of the flow passages of the catheter, to seal those passages when not in use. For example, the hub 18 may house one or more valve assemblies 20 which are designed to seal the lumen(s) of the catheter 10 under certain conditions, and to allow passage of fluid therethrough under other conditions. In an exemplary case applicable to a dialysis catheter, the system of valves may seal the catheter 10 when it is not connected to an operating dialysis machine, and may allow both an outflow of non-purified blood and an inflow of purified blood to the patient when an operating dialysis machine is connected thereto. These valve assemblies 20 thus selectively allow flow into or out of the patient only under predetermined conditions when they are placed in fluid contact with the inflow or outflow portions of a dialysis catheter 10. For example, the valve 22 may be located between a patient vascular line 24 which is in fluid connection with the patient's vascular system, and the external line 14, which is connectable to the dialysis machine.
Pressure activated safety valves (PASV's) are one type of flow control device that has been used to seal vascular catheters when not in use. These valves open when subject to flow pressure of at least a pre-determined threshold value and remain closed when subject to flow pressures below the pre-determined threshold value. In the exemplary case of a PASV used in a dialysis catheter, the valve is preferably designed so that the pre-determined pressure substantially exceeds a pressure to which the valve would be subjected from the vascular system or due to patient activity. The pre-determined threshold pressure may correspond to a pressure approximating a lower level of the pressures to which the valve would be subjected by an operating dialysis machine. Thus, when no dialysis machine is connected to the catheter, the pressure in the lumen is insufficient to open the PASV, and the catheter remains sealed.
A typical PASV comprises an housing through which the flow of a liquid passes from an inlet portion to an outlet portion. A slitted membrane is disposed within the housing, generally perpendicular to the direction of flow. The slitted membrane is the flow control element of the valve, and may be formed of an elastic material which can deform to a certain extent under the pressure of the fluid. The material, however, is sufficiently resilient so that the slit remain substantially closed unless a pressure above a selected threshold pressure is applied to the membrane by the fluid. In that configuration, the membrane is closed and no fluid can flow through the membrane, thus through the valve. If the fluid pressure rises above the threshold value, the resilience of the membrane material is overcome, and the slit opens. In this open configuration, the fluid is allowed through the membrane and thus through the valve. The threshold pressure may be selected to be below a pressure applied to the fluid by an operating dialysis machine, but well above a pressure normally existing in a vascular system.
Due to the design of conventional PASV slitted membranes, the fluid (typically blood) is accelerated while passing through the orifice formed by the slit of the membrane. According to Bernoulli's equation, the pressure of the fluid is inversely proportional to the fluid's velocity, thus the fluid pressure drops through the slit as its velocity increases through the narrow orifice. The velocity reaches a minimum value at a point called the vena contracta. If the pressure of the fluid falls below its vapor pressure, some of the gases contained in the liquid (i.e. blood) may come out of solution, and form gas bubbles within the liquid. These bubbles may cause serious problems in blood, because they may travel through the patient's vascular system and may become lodged in a blood vessel, which as a result may be totally or partially blocked. In addition, the formation of bubbles may interfere with the flow of blood through the valve, reducing the device's performance
The problems described above may be alleviated by utilizing a pressure control element built into the valve to manage the pressure of the fluid flowing therethrough.
In one exemplary embodiment, the pressure drop across the valve 100 is managed by providing the PASV with multiple slitted membranes rather than one single membrane, as is done conventionally. As shown in
In the exemplary embodiment depicted there are two membranes 120, 122 that prevent flow of fluid through the valve 100. As a result, each of the membranes may have a smaller modulus or may be thinner, so that it is more easily openable. Accordingly, each of membranes 120 and 122 may require a lower pressure to open fully, causes a smaller pressure drop, and thus results in a smaller increase in velocity of the fluid flowing through the corresponding slits 126, 128. For example, flow entering the valve 100 through the luer housing 102 initially encounters first slitted membrane 120. If the pressure of the fluid is below the threshold pressure for the valve 100, the fluid will not pass through the complete valve 100. This case corresponds to the situation where the dialysis machine is not connected to the catheter.
Since the first membrane 120 has less resistance to opening than a corresponding single flow control membrane, some of the fluid may pass through the slit 126. However, since there is more than one membrane in the valve 100, the small amount of flow which passes through membrane 120 into the midsection housing 124 can be completely retained by the second membrane 122. The pressure of the fluid in midsection housing 124 is further reduced by the passage through slit 126. The second slitted membrane 122 will then easily prevent further flow of the fluid, since the pressure of the fluid in midsection housing 124 is insufficient to open slit 128.
In the case where the luer housing 102 is connected to an operating dialysis machine, the flow entering the valve 100 will be at a pressure above the valve's threshold pressure. Both slits 126, 128 of slitted membranes 120, 122 will then open under that pressure and will let the fluid pass. However, since each slitted membrane 120, 122 absorbs only a partial pressure drop, lower than the total pressure drop across the valve 100, the pressure of the blood is never reduced to the vapor pressure. The blood flowing through valve 100 thus does not experience cavitation. In the exemplary embodiment shown in
As indicated above, the pressure decrease in the blood is related to the increase in velocity through the valve 100. To further reduce the pressure drop, it is beneficial to introduce in the design of valve 100 additional features adapted to reduce the flow velocity in the housing rather than across the slitted membranes. For example, the orientation of the slits 126, 128 may be selected to further reduce the blood velocity in midsection housing 124. In one exemplary embodiment depicted in
In addition or instead of orienting successive slitted membranes in a staggered configuration, the velocity of the blood flow may also be reduced by using different slit configurations on the membranes. For example, membrane 120 may be formed with a linear slit 126, while membrane 122 may be formed with an S-shaped slit. In this case too, the flow of blood has to change direction to pass from one slitted membrane to the other, which further reduces the flow's velocity and maintains a higher pressure of the flow.
The larger the flow area available for the flow of blood, the lower the fluid velocity tends to be. Accordingly, it may be beneficial to increase the size of the slits in the flow control membrane(s) of valve 100, and/or to increase the size of the body portion 106, particularly near the slitted membranes. In one exemplary embodiment, the membranes 120, 122 may be thinner than a comparable single membrane, so that a larger opening may be obtained from the slits 126, 128 in the open configuration, for a given flow pressure. As described above, two membranes which are more easily opened than a single membrane can still be capable of remaining closed when the flow pressure is below the valve's threshold pressure. An increase in the length “l” of the slits 126, 128 can achieve the same result. The thickness and slit length “l” of the membranes 120, 122 may thus be selected to obtain a desired minimum flow area of the slits 126, 128, in the open configuration. An increase in dimensions of the midsection housing 124, and/or of the barb and luer housings 102, 104 may also be used to accommodate the longer slits of the membranes.
In an exemplary embodiment, the length of the slit(s) 126, 128 may be increased from a conventional value of about 6.6 mm to about 9.0 mm, resulting in an increase in flow area in the open configuration of about 150%. In another exemplary embodiment, a reduction in the thickness and/or the modulus of one or all the slitted membranes 120, 122 used in valve 100 may provide an increase of flow area of about 130%.
Another exemplary embodiment having more than one slitted membrane, according to the present invention, is shown in
Another embodiment according to the present invention comprises one or more slitted membranes which are also beveled or otherwise sculpted to direct the flow towards the slit. For example, the slitted membrane 216 shown in
Another problem that may occur in conventional PASV's is that some blood cells may be damaged by the passage through the slitted membranes at high flow rates. More specifically, areas of flow separation in the valve housing may cause some of the blood to recirculate within the housing, and may cause loss of patency and hemolysis, or the damage of red blood cells. Extended residence time of the blood in the valve may also promote the formation of deposits, or thrombi, which may break off and become lodged in the patient's blood vessels. As shown in
As shown in
According to exemplary embodiments of the present invention, the areas of recirculation in the PASV may be reduced by constructing the luer and/or barb housings so that flow separation does not occur. For example, as shown in
As described above, various configurations of the slitted membranes used in the PASV according to the present invention may be used to control and direct the flow of fluid through the valve 280. For example, the shape and orientation of the slit(s) may be used to direct the flow of blood towards areas of low flow or recirculation, to complement the effect of the tapered luer housing wall described above. One or more slitted membranes such as the membranes 120, 122 described in
The present invention has been described with reference to specific embodiments, more specifically to a pressure activated safety valve used in a blood dialysis catheter. However, other embodiments may be devised that are applicable to other medical devices, without departing from the scope of the invention. Accordingly, various modifications and changes may be made to the embodiments without departing from the broadest spirit and scope of the present invention as set forth in the claims that follow. The specification and drawings are accordingly to be regarded in an illustrative rather than a restrictive sense.
Number | Name | Date | Kind |
---|---|---|---|
2446571 | Browne | Mar 1944 | A |
2720881 | Weaver et al. | Oct 1955 | A |
2755060 | Twyman | Jul 1956 | A |
3113586 | Edmark, Jr. | Dec 1963 | A |
3159175 | MacMillan | Dec 1964 | A |
3159176 | Russell et al. | Dec 1964 | A |
3477438 | Allen et al. | Nov 1969 | A |
3514438 | Nelsen et al. | May 1970 | A |
3525357 | Koreski | Aug 1970 | A |
3621557 | Cushman et al. | Nov 1971 | A |
3669323 | Harker et al. | Jun 1972 | A |
3673612 | Merrill et al. | Jul 1972 | A |
3674183 | Venable et al. | Jul 1972 | A |
3710942 | Rosenberg | Jan 1973 | A |
3788327 | Donowitz et al. | Jan 1974 | A |
3811466 | Ohringer | May 1974 | A |
3941149 | Mittleman | Mar 1976 | A |
3955594 | Snow | May 1976 | A |
4072146 | Howes | Feb 1978 | A |
4142525 | Binard et al. | Mar 1979 | A |
4143853 | Abramson | Mar 1979 | A |
4244379 | Smith | Jan 1981 | A |
4387879 | Tauschinski | Jun 1983 | A |
4405316 | Mittleman | Sep 1983 | A |
4434810 | Atkinson | Mar 1984 | A |
4447237 | Frisch et al. | May 1984 | A |
4468224 | Enzmann et al. | Aug 1984 | A |
4502502 | Krug | Mar 1985 | A |
4524805 | Hoffman | Jun 1985 | A |
4543087 | Sommercorn et al. | Sep 1985 | A |
4552553 | Schulte et al. | Nov 1985 | A |
4610665 | Matsumoto et al. | Sep 1986 | A |
4616768 | Flier | Oct 1986 | A |
4646945 | Steiner et al. | Mar 1987 | A |
4673393 | Suzuki et al. | Jun 1987 | A |
4681572 | Tokarz et al. | Jul 1987 | A |
4692146 | Hilger | Sep 1987 | A |
4722725 | Sawyer et al. | Feb 1988 | A |
4790832 | Lopez | Dec 1988 | A |
4798594 | Hillstead | Jan 1989 | A |
4801297 | Mueller | Jan 1989 | A |
4908028 | Colon et al. | Mar 1990 | A |
4944726 | Hilal et al. | Jul 1990 | A |
4946448 | Richmond | Aug 1990 | A |
4960412 | Fink | Oct 1990 | A |
5000745 | Guest et al. | Mar 1991 | A |
5009391 | Steigerwald | Apr 1991 | A |
5030210 | Alchas et al. | Jul 1991 | A |
5084015 | Moriuchi | Jan 1992 | A |
5098405 | Peterson et al. | Mar 1992 | A |
5125893 | Dryden | Jun 1992 | A |
5147332 | Moorehead | Sep 1992 | A |
5149327 | Oshiyama | Sep 1992 | A |
5167638 | Felix et al. | Dec 1992 | A |
5169393 | Moorehead et al. | Dec 1992 | A |
5176652 | Littrell | Jan 1993 | A |
5176662 | Bartholomew et al. | Jan 1993 | A |
5201722 | Moorehead et al. | Apr 1993 | A |
5205834 | Moorehead et al. | Apr 1993 | A |
5249598 | Schmidt | Oct 1993 | A |
5254086 | Palmer et al. | Oct 1993 | A |
5324274 | Martin | Jun 1994 | A |
5330424 | Palmer et al. | Jul 1994 | A |
5336203 | Goldhardt et al. | Aug 1994 | A |
5360407 | Leonard et al. | Nov 1994 | A |
5370624 | Edwards et al. | Dec 1994 | A |
5395352 | Penny | Mar 1995 | A |
5396925 | Poli et al. | Mar 1995 | A |
5399168 | Wadsworth et al. | Mar 1995 | A |
5401255 | Sutherland et al. | Mar 1995 | A |
D357735 | McPhee | Apr 1995 | S |
5405340 | Fageol et al. | Apr 1995 | A |
5411491 | Goldhardt et al. | May 1995 | A |
5453097 | Paradis | Sep 1995 | A |
5454784 | Atkinson et al. | Oct 1995 | A |
5469805 | Gibbs et al. | Nov 1995 | A |
5470305 | Arnett et al. | Nov 1995 | A |
5484420 | Russo | Jan 1996 | A |
5542923 | Ensminger et al. | Aug 1996 | A |
5545150 | Danks et al. | Aug 1996 | A |
5554136 | Luther | Sep 1996 | A |
5562618 | Cai et al. | Oct 1996 | A |
5571093 | Cruz et al. | Nov 1996 | A |
5575769 | Vaillancourt et al. | Nov 1996 | A |
5624395 | Mikhail et al. | Apr 1997 | A |
5637099 | Durdin et al. | Jun 1997 | A |
5667500 | Palmer et al. | Sep 1997 | A |
5707357 | Mikhail et al. | Jan 1998 | A |
5743873 | Cai et al. | Apr 1998 | A |
5743884 | Hasson et al. | Apr 1998 | A |
5743894 | Swisher | Apr 1998 | A |
5752938 | Flatland et al. | May 1998 | A |
5803078 | Brauner | Sep 1998 | A |
5807349 | Person et al. | Sep 1998 | A |
5810789 | Powers et al. | Sep 1998 | A |
5843044 | Moorehead | Dec 1998 | A |
5853397 | Shemesh et al. | Dec 1998 | A |
5865308 | Qin et al. | Feb 1999 | A |
5944698 | Fischer et al. | Aug 1999 | A |
5984902 | Moorehead | Nov 1999 | A |
5989233 | Yoon | Nov 1999 | A |
6033393 | Balbierz et al. | Mar 2000 | A |
6045734 | Luther et al. | Apr 2000 | A |
6050934 | Mikhail et al. | Apr 2000 | A |
6056717 | Finch et al. | May 2000 | A |
6062244 | Arkans | May 2000 | A |
6092551 | Bennett | Jul 2000 | A |
6099505 | Ryan et al. | Aug 2000 | A |
6120483 | Davey et al. | Sep 2000 | A |
6152909 | Bagaoisan et al. | Nov 2000 | A |
6210366 | Sanfilippo | Apr 2001 | B1 |
6227200 | Crump et al. | May 2001 | B1 |
6270489 | Wise et al. | Aug 2001 | B1 |
6306124 | Jones et al. | Oct 2001 | B1 |
6364861 | Feith et al. | Apr 2002 | B1 |
6364867 | Wise et al. | Apr 2002 | B2 |
6375637 | Campbell et al. | Apr 2002 | B1 |
6436077 | Davey et al. | Aug 2002 | B1 |
6442415 | Bis et al. | Aug 2002 | B1 |
6446671 | Armenia et al. | Sep 2002 | B2 |
6508791 | Guerrero | Jan 2003 | B1 |
6551270 | Bimbo et al. | Apr 2003 | B1 |
6610031 | Chin | Aug 2003 | B1 |
6726063 | Stull et al. | Apr 2004 | B2 |
6786884 | DeCant et al. | Sep 2004 | B1 |
6874999 | Dai et al. | Apr 2005 | B2 |
6953450 | Baldwin et al. | Oct 2005 | B2 |
6994314 | Garnier et al. | Feb 2006 | B2 |
7081106 | Guo et al. | Jul 2006 | B1 |
7252652 | Moorehead et al. | Aug 2007 | B2 |
7291133 | Kindler et al. | Nov 2007 | B1 |
7316655 | Garibotto et al. | Jan 2008 | B2 |
7435236 | Weaver et al. | Oct 2008 | B2 |
7601141 | Dikeman et al. | Oct 2009 | B2 |
7637893 | Christensen et al. | Dec 2009 | B2 |
7758541 | Wallace et al. | Jul 2010 | B2 |
20010023333 | Wisse et al. | Sep 2001 | A1 |
20010037079 | Burbank et al. | Nov 2001 | A1 |
20020010425 | Guo et al. | Jan 2002 | A1 |
20020016584 | Wise et al. | Feb 2002 | A1 |
20020121530 | Socier | Sep 2002 | A1 |
20020156430 | Haarala et al. | Oct 2002 | A1 |
20020165492 | Davey et al. | Nov 2002 | A1 |
20020193752 | Lynn | Dec 2002 | A1 |
20030122095 | Wilson et al. | Jul 2003 | A1 |
20040034324 | Seese et al. | Feb 2004 | A1 |
20040064128 | Raijman et al. | Apr 2004 | A1 |
20040102738 | Dikeman | May 2004 | A1 |
20040108479 | Garnier et al. | Jun 2004 | A1 |
20040186444 | Daly et al. | Sep 2004 | A1 |
20040193119 | Canaud et al. | Sep 2004 | A1 |
20040210194 | Bonnette et al. | Oct 2004 | A1 |
20040267185 | Weaver et al. | Dec 2004 | A1 |
20050004955 | Lee et al. | Jan 2005 | A1 |
20050010176 | Dikeman et al. | Jan 2005 | A1 |
20050027261 | Weaver et al. | Feb 2005 | A1 |
20050043703 | Nordgren | Feb 2005 | A1 |
20050049555 | Moorehead et al. | Mar 2005 | A1 |
20050149116 | Edwards et al. | Jul 2005 | A1 |
20050171490 | Weaver et al. | Aug 2005 | A1 |
20050171510 | DiCarlo et al. | Aug 2005 | A1 |
20050283122 | Nordgren | Dec 2005 | A1 |
20060129092 | Hanlon et al. | Jun 2006 | A1 |
20060135949 | Rome et al. | Jun 2006 | A1 |
20060149211 | Simpson et al. | Jul 2006 | A1 |
20070161940 | Blanchard et al. | Jul 2007 | A1 |
20070161970 | Spohn et al. | Jul 2007 | A1 |
20070276313 | Moorehead et al. | Nov 2007 | A1 |
20080108956 | Lynn et al. | May 2008 | A1 |
20090292252 | Lareau et al. | Nov 2009 | A1 |
Number | Date | Country |
---|---|---|
20208420 | Oct 2002 | DE |
0128525 | Dec 1984 | EP |
0337617 | Oct 1989 | EP |
0474069 | Mar 1992 | EP |
0864336 | Sep 1998 | EP |
0930082 | Jul 1999 | EP |
1016431 | Jul 2000 | EP |
2508008 | Dec 1982 | FR |
2718969 | Oct 1995 | FR |
966137 | Aug 1964 | GB |
2102398 | Feb 1983 | GB |
59133877 | Aug 1984 | JP |
63255057 | Oct 1988 | JP |
9038197 | Feb 1997 | JP |
WO-8902764 | Apr 1989 | WO |
9206732 | Apr 1992 | WO |
9516480 | Jun 1995 | WO |
WO-9617190 | Jun 1996 | WO |
WO-9623158 | Aug 1996 | WO |
WO-9641649 | Dec 1996 | WO |
9723255 | Jul 1997 | WO |
9726831 | Jul 1997 | WO |
WO-9822178 | May 1998 | WO |
9942166 | Aug 1999 | WO |
WO-0006230 | Feb 2000 | WO |
0044419 | Aug 2000 | WO |
WO-0174434 | Oct 2001 | WO |
03084832 | Oct 2003 | WO |
2005023355 | Mar 2005 | WO |
WO-2008089985 | Jul 2008 | WO |
Number | Date | Country | |
---|---|---|---|
20060184139 A1 | Aug 2006 | US |